| John Tyler Whitaker, DO | |
|
1705 E 19th St Ste 302, Tulsa, OK 74104-5410 | |
| (918) 748-7585 | |
| (918) 403-6352 |
| Full Name | John Tyler Whitaker |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 12 Years |
| Location | 1705 E 19th St Ste 302, Tulsa, Oklahoma |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1205195443 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | 5464 (Oklahoma) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Hillcrest Medical Center | Tulsa, OK | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Crossover Community Impact Inc | 0345468625 | 4 |
| Hospitalist Medicine Physicians Of Texas Pllc | 3476688318 | 951 |
| Tulsa Hospital Medicine Physicians Group, Llc | 7214327832 | 116 |
News Archive
In what the researchers say could be promising news in the quest to find a therapy to slow the progression of amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease, scientists at the University of California, San Diego (UCSD) School of Medicine have shown that targeting neuronal support cells called astrocytes sharply slows disease progression in mice.
Diseases affecting the kidneys represent a major and unsolved health issue worldwide. The kidneys rarely recover function once they are damaged by disease, highlighting the urgent need for better knowledge of kidney development and physiology.
Amorfix Life Sciences Ltd. and reMYND NV today announced the signing of a partnership agreement to offer the Amorfix A4 amyloid testing service to reMYND's contract research clients. reMYND's contract research business offers an extensive portfolio of preclinical in-vivo efficacy, pharmacokinetic and safety testing of experimental Alzheimer therapies using proprietary mouse models of Alzheimer's disease (AD).
Primagen Holding BV has announced that the U.S. Patent and Trademark Office has granted a patent for its Mitox mitochondrial DNA quantification technology as biomarkers for efficacy and adverse events of treatment.
› Verified 2 days ago
| Entity Name | St John Physicians Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1336194406 PECOS PAC ID: 2567366495 Enrollment ID: O20031121000867 |
News Archive
In what the researchers say could be promising news in the quest to find a therapy to slow the progression of amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease, scientists at the University of California, San Diego (UCSD) School of Medicine have shown that targeting neuronal support cells called astrocytes sharply slows disease progression in mice.
Diseases affecting the kidneys represent a major and unsolved health issue worldwide. The kidneys rarely recover function once they are damaged by disease, highlighting the urgent need for better knowledge of kidney development and physiology.
Amorfix Life Sciences Ltd. and reMYND NV today announced the signing of a partnership agreement to offer the Amorfix A4 amyloid testing service to reMYND's contract research clients. reMYND's contract research business offers an extensive portfolio of preclinical in-vivo efficacy, pharmacokinetic and safety testing of experimental Alzheimer therapies using proprietary mouse models of Alzheimer's disease (AD).
Primagen Holding BV has announced that the U.S. Patent and Trademark Office has granted a patent for its Mitox mitochondrial DNA quantification technology as biomarkers for efficacy and adverse events of treatment.
› Verified 2 days ago
| Entity Name | Crossover Community Impact Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1407297963 PECOS PAC ID: 0345468625 Enrollment ID: O20140828000563 |
News Archive
In what the researchers say could be promising news in the quest to find a therapy to slow the progression of amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease, scientists at the University of California, San Diego (UCSD) School of Medicine have shown that targeting neuronal support cells called astrocytes sharply slows disease progression in mice.
Diseases affecting the kidneys represent a major and unsolved health issue worldwide. The kidneys rarely recover function once they are damaged by disease, highlighting the urgent need for better knowledge of kidney development and physiology.
Amorfix Life Sciences Ltd. and reMYND NV today announced the signing of a partnership agreement to offer the Amorfix A4 amyloid testing service to reMYND's contract research clients. reMYND's contract research business offers an extensive portfolio of preclinical in-vivo efficacy, pharmacokinetic and safety testing of experimental Alzheimer therapies using proprietary mouse models of Alzheimer's disease (AD).
Primagen Holding BV has announced that the U.S. Patent and Trademark Office has granted a patent for its Mitox mitochondrial DNA quantification technology as biomarkers for efficacy and adverse events of treatment.
› Verified 2 days ago
| Entity Name | Hospitalist Medicine Physicians Of Texas Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629307095 PECOS PAC ID: 3476688318 Enrollment ID: O20180326002260 |
News Archive
In what the researchers say could be promising news in the quest to find a therapy to slow the progression of amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease, scientists at the University of California, San Diego (UCSD) School of Medicine have shown that targeting neuronal support cells called astrocytes sharply slows disease progression in mice.
Diseases affecting the kidneys represent a major and unsolved health issue worldwide. The kidneys rarely recover function once they are damaged by disease, highlighting the urgent need for better knowledge of kidney development and physiology.
Amorfix Life Sciences Ltd. and reMYND NV today announced the signing of a partnership agreement to offer the Amorfix A4 amyloid testing service to reMYND's contract research clients. reMYND's contract research business offers an extensive portfolio of preclinical in-vivo efficacy, pharmacokinetic and safety testing of experimental Alzheimer therapies using proprietary mouse models of Alzheimer's disease (AD).
Primagen Holding BV has announced that the U.S. Patent and Trademark Office has granted a patent for its Mitox mitochondrial DNA quantification technology as biomarkers for efficacy and adverse events of treatment.
› Verified 2 days ago
| Entity Name | Cogent Healthcare Of Texas Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1992722953 PECOS PAC ID: 8628076924 Enrollment ID: O20210209000102 |
News Archive
In what the researchers say could be promising news in the quest to find a therapy to slow the progression of amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease, scientists at the University of California, San Diego (UCSD) School of Medicine have shown that targeting neuronal support cells called astrocytes sharply slows disease progression in mice.
Diseases affecting the kidneys represent a major and unsolved health issue worldwide. The kidneys rarely recover function once they are damaged by disease, highlighting the urgent need for better knowledge of kidney development and physiology.
Amorfix Life Sciences Ltd. and reMYND NV today announced the signing of a partnership agreement to offer the Amorfix A4 amyloid testing service to reMYND's contract research clients. reMYND's contract research business offers an extensive portfolio of preclinical in-vivo efficacy, pharmacokinetic and safety testing of experimental Alzheimer therapies using proprietary mouse models of Alzheimer's disease (AD).
Primagen Holding BV has announced that the U.S. Patent and Trademark Office has granted a patent for its Mitox mitochondrial DNA quantification technology as biomarkers for efficacy and adverse events of treatment.
› Verified 2 days ago
| Entity Name | Tulsa Hospital Medicine Physicians Group, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1144982711 PECOS PAC ID: 7214327832 Enrollment ID: O20211214000389 |
News Archive
In what the researchers say could be promising news in the quest to find a therapy to slow the progression of amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease, scientists at the University of California, San Diego (UCSD) School of Medicine have shown that targeting neuronal support cells called astrocytes sharply slows disease progression in mice.
Diseases affecting the kidneys represent a major and unsolved health issue worldwide. The kidneys rarely recover function once they are damaged by disease, highlighting the urgent need for better knowledge of kidney development and physiology.
Amorfix Life Sciences Ltd. and reMYND NV today announced the signing of a partnership agreement to offer the Amorfix A4 amyloid testing service to reMYND's contract research clients. reMYND's contract research business offers an extensive portfolio of preclinical in-vivo efficacy, pharmacokinetic and safety testing of experimental Alzheimer therapies using proprietary mouse models of Alzheimer's disease (AD).
Primagen Holding BV has announced that the U.S. Patent and Trademark Office has granted a patent for its Mitox mitochondrial DNA quantification technology as biomarkers for efficacy and adverse events of treatment.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| John Tyler Whitaker, DO 1705 E 19th St Ste 302, Tulsa, OK 74104-5410 Ph: (918) 748-7585 | John Tyler Whitaker, DO 1705 E 19th St Ste 302, Tulsa, OK 74104-5410 Ph: (918) 748-7585 |
News Archive
In what the researchers say could be promising news in the quest to find a therapy to slow the progression of amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease, scientists at the University of California, San Diego (UCSD) School of Medicine have shown that targeting neuronal support cells called astrocytes sharply slows disease progression in mice.
Diseases affecting the kidneys represent a major and unsolved health issue worldwide. The kidneys rarely recover function once they are damaged by disease, highlighting the urgent need for better knowledge of kidney development and physiology.
Amorfix Life Sciences Ltd. and reMYND NV today announced the signing of a partnership agreement to offer the Amorfix A4 amyloid testing service to reMYND's contract research clients. reMYND's contract research business offers an extensive portfolio of preclinical in-vivo efficacy, pharmacokinetic and safety testing of experimental Alzheimer therapies using proprietary mouse models of Alzheimer's disease (AD).
Primagen Holding BV has announced that the U.S. Patent and Trademark Office has granted a patent for its Mitox mitochondrial DNA quantification technology as biomarkers for efficacy and adverse events of treatment.
› Verified 2 days ago
Prasoon Kumar Yendluri, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 6161 S Yale Ave, Tulsa, OK 74136 Phone: 918-502-1900 Fax: 918-494-6303 | |
Janet Elizabeth Cheek, DO Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1145 S Utica Ave, Ste 460, Tulsa, OK 74104 Phone: 918-579-5749 Fax: 918-579-5762 | |
Edie Ann Carey, D.O. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1145 S Utica Ave, Ste 460, Tulsa, OK 74104 Phone: 918-579-5749 Fax: 918-579-5762 | |
Dr. Brandon Micheal Bailey, DO Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 2811 E 15th St Ste 102, Tulsa, OK 74104 Phone: 918-935-3240 Fax: 918-935-3241 | |
Kendra Wilson, DO Hospitalist Medicare: Medicare Enrolled Practice Location: 6161 S Yale Ave, Tulsa, OK 74136 Phone: 918-502-1900 Fax: 918-494-6303 | |
Radhika Kothakota, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 6161 S Yale Ave, Tulsa, OK 74136 Phone: 918-488-6045 Fax: 918-488-6098 | |
Dr. Gulshan Dangol, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1145 S Utica Ave Ste 460, Tulsa, OK 74104 Phone: 918-579-5749 Fax: 918-579-5762 |